(Q45235855)

English

Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.

scientific article published on 16 October 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B. (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

attenuated vaccine

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

0 references

1 reference

based on heuristic

inferred from title

Carmen E Gómez

1

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Giuseppe Pantaleo

9

object named as

Giuseppe Pantaleo

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Mariano Esteban

10

object named as

Mariano Esteban

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

5

object named as

Ralf Wagner

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Jose Luis Nájera

2

object named as

Jose Luis Nájera

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Marie-Joelle Frachette

7

object named as

Marie-Joelle Frachette

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Peter Liljeström

8

object named as

Peter Liljeström

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

author name string

Eva Pérez Jiménez

3

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Victoria Jiménez

4

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Marcus Graf

6

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

language of work or name

0 references

publication date

16 October 2006

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

25

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

2863-2885

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Can we reverse the HIV/AIDS pandemic with an expanded response?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.090

7 January 2021

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.090

7 January 2021

The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.090

7 January 2021

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.090

7 January 2021

Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.090

7 January 2021

Studies using a viral challenge and CD8 T cell depletions on the roles of cellular and humoral immunity in the control of an SHIV-89.6P challenge in DNA/MVA-vaccinated macaques.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.090

7 January 2021

A striking property of recombinant poxviruses: efficient inducers of in vivo expansion of primed CD8(+) T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.090

7 January 2021

Recombinant viruses as a tool for therapeutic vaccination against human cancers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.090

7 January 2021

Attenuated poxviruses expressing a synthetic HIV protein stimulate HLA-A2-restricted cytotoxic T-cell responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.090

7 January 2021

Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.090

7 January 2021

Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.090

7 January 2021

Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.090

7 January 2021

Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.090

7 January 2021

Potentiation of simian immunodeficiency virus (SIV)-specific CD4(+) and CD8(+) T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.090

7 January 2021

Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.090

7 January 2021

Compact, synthetic, vaccinia virus early/late promoter for protein expression.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.090

7 January 2021

HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.090

7 January 2021

Quantification of antigen specific CD8+ T cells using an ELISPOT assay

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.090

7 January 2021

Host response to the attenuated poxvirus vector NYVAC: upregulation of apoptotic genes and NF-kappaB-responsive genes in infected HeLa cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.090

7 January 2021

Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.090

7 January 2021

Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.090

7 January 2021

Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.090

7 January 2021

Role of cytokines and chemokines in the regulation of innate immunity and HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.090

7 January 2021

Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.090

7 January 2021

Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.090

7 January 2021

Apoptotic cells deliver processed antigen to dendritic cells for cross-presentation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.090

7 January 2021

Death-defying immunity: do apoptotic cells influence antigen processing and presentation?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.090

7 January 2021

Immunodominance in virus-induced CD8(+) T-cell responses is dramatically modified by DNA immunization and is regulated by gamma interferon

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.090

7 January 2021

Competition Between CTL Narrows the Immune Response Induced by Prime-Boost Vaccination Protocols

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.090

7 January 2021

The rapidity with which virus-specific CD8+ T cells initiate IFN-gamma synthesis increases markedly over the course of infection and correlates with immunodominance

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.090

7 January 2021

Impact of intrapeptide epitope location on CD8 T cell recognition

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.090

7 January 2021

Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.090

7 January 2021

Studies in subjects with long-term nonprogressive human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.090

7 January 2021

Maintenance of large numbers of virus-specific CD8+ T cells in HIV-infected progressors and long-term nonprogressors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.090

7 January 2021

Clinical trials of HIV vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.090

7 January 2021

Elevated T cell counts and RANTES expression in the genital mucosa of HIV-1-resistant Kenyan commercial sex workers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.090

7 January 2021

The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.090

7 January 2021

NYVAC: a highly attenuated strain of vaccinia virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.090

7 January 2021

Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.090

7 January 2021

HLA class I-restricted responses to vaccinia recognize a broad array of proteins mainly involved in virulence and viral gene regulation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.090

7 January 2021

Enhanced CD8+ T cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.090

7 January 2021

Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.090

7 January 2021

Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.090

7 January 2021

Enhanced simian immunodeficiency virus-specific immune responses in macaques induced by priming with recombinant Semliki Forest virus and boosting with modified vaccinia virus Ankara.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.090

7 January 2021

Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.090

7 January 2021

Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.090

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2006.09.090

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45235855&oldid=1743023705"